On April 23, 2024, Zydus Lifesciences Limited informed in an exchange filing that the New Drug Application (NDA) of Desidustat Tablets has been accepted by the National Medical Products Administration of China (NMPA). CMS International Development and Management Limited, a wholly-owned subsidiary of China Medical System Holdings Limited (CMS) obtained an exclusive licence for the …